Key Takeaways
- Domestic flat, acute stress: India business was flat as acute therapies faced unpredictable primary sales, though secondary prescriptions held up and management is confident of returning to IPM-level growth.
- Gross margin jumps 300 bps QoQ: Both subsidiaries stopped being a drain and standalone COGS improved on better portfolio mix, a structural lift that management expects to sustain.
- US business now real commercial revenue: Earlier INR300 cr quarters included INR30-40 cr of milestone payments; this quarter's sales are almost entirely commercial, with visibility to return to that INR300 cr level at better margins.
- Europe poised for inflection: Approvals delayed by a quarter are now clearing, supply constraints are resolving, and management targets 20%+ revenue growth with improving margins over the next few years.
- What to watch next quarter: Whether Europe delivers the promised Q4 bounce, the pace of API ramp-up from the Auric site, and any movement on the Goa Plant II US FDA warning letter.
India Formulations: Acute Headwinds, Prescription Resilience
- Primary vs secondary disconnect: Acute therapies showed stress at the primary sales level due to unpredictable quarter-to-quarter stocking patterns, but secondary sales and prescription response remain intact, with management arguing real consumption is not slowing.
- Cyclopam as a case study: Last year Cyclopam grew 30% at primary with prescriptions up 16%; this year primary is down 15% but prescriptions continue to grow, illustrating that primary push and hold-back patterns, not demand erosion, are driving the blips.
- Cardio-diabeto strategy: A tough, competitive segment where Indoco focuses on therapies allowing a higher prescriber base, increasingly targeting consulting physicians, pediatricians and gynecologists rather than fighting incumbents head-on.
- Tier 2/3 strength, metro push: Over 60% of India revenues come from Tier 3 down to Tier 2; the strategy is to shift from acute to subchronic, from GPs to mass specialty, and improve metro performance.
- December performance context: December was at par or better than the covered market; the gap versus IPM appears only when anti-obesity products are included in the benchmark.
Aditi Panandikar: "I feel going forward, we must discuss India business more on a YTD or a MAT basis that is far better."
Europe: Delayed Approvals Clearing, Margin Story Building
- Q3 shortfall was timing, not demand: Approvals got pushed forward by one quarter due to delays between customer and Indoco; 90% of the work is done and Q4 should capture at least 1-1.5 months of manufacturing that slipped.
- Supply constraints ending: Europe revenue was also down because of inability to supply one product; the company is transferring it to a site that has undergone MMP and can take larger batches, and all of that should end this quarter so next year starts with a clean slate.
- Longer-term trajectory: Management expects Europe to grow at 20% plus in revenues over the next few years, with margins improving on that business, and sees a path to INR400-500 cr by FY28 or FY29.
- Near-term run rate: Over the next couple of years, stabilizing at around a 13-14% run rate; a couple of years after that, should be able to pitch for much higher growth.
Aditi Panandikar: "I'm not just looking at top line growth, but we should look at Europe over the next few years as growing at 20% plus in revenues. But more importantly, we should be watching the margins to improve on that business."
US Business: Commercial Revenue Replaces Milestones
- Revenue quality transformed: Earlier quarters where the US business did INR300 crores included INR30-40 crores of milestone payments from Teva or upfront R&D cost coverage; this quarter's sales are almost entirely from commercial product sales, making the base far more sustainable.
- Visibility on INR300 cr return: Management has definite visibility on getting back to INR300 crores, and margins should be far better than when they did it earlier because plants have been optimized.
- Goa Plant II status unchanged: Only Goa Plant II is under the US FDA cloud; Goa Plant I (solid oral site) is not affected and many new launches come from solid oral sites. On the warning letter, management said only "Waiting. We are waiting."
- Cautious on timing: Management explicitly cautioned against expecting month-by-month linearity, noting that the US business does not work that way.
Aditi Panandikar: "But I would be little cautious because the moment I say something to you guys, you expect the next month to do well. But US business is not like this."
API & Auric Site: Consolidation Year Before Ramp-Up
- Patalganga margin lift: The Patalganga site produces finished APIs; the Auric site (Warren Remedies) has started making KSMs and starting material consumed at Patalganga, freeing capacity for finished API, and this is already showing in results.
- Patalganga EIR clean: The site received its EIR for the US FDA audit with Zero 483s, a regulatory milestone that de-risks the API supply chain.
- FY27 is a consolidation year: Next year will be a year of consolidation for API with a lot of validation of products at the Auric site; management expects muted top line from API in Warren Remedies for FY27.
- Ramp-up in 8-10 months: The finished API block at Auric is ready and taking validation batches; once US FDA or EU qualifies it, the company can sell into regulated markets and see further margin improvement, with high revenues expected in 8-10 months.
Aditi Panandikar: "I'm sure that in another 8 to 10 months, we will start getting high revenues from Auric site also and then we can really ramp up our API business."
Subsidiaries & Portfolio: OTC Momentum, FPP Build-Out
- Warren Remedies growth drivers: Growth is driven by OTC and OTX brands: Sensodent-KF (switched from Rx to OTX to OTC) and Kidodent doing exceedingly well in OTX. New toothpaste launches include Sensodent DSP and Sensodent DPC, entering the clean toothpaste segment.
- Warren Remedies breakeven: Management is not pushing for near-term breakeven, noting that expecting it in the second year is very tough because advertising spend has just started ramping up.
- OTC growth commitment: With the energy being put into consumer marketing and advertising, the OTC number should go up safely by at least 30% next year.
- FPP portfolio building: FPP was acquired in June 2023 with a small traded-product portfolio; over two years the company has built a portfolio with Indoco-supplied solid orals and sterile products. Solids have started doing very well; sterile products from Plant II are not very significant and are now being sourced from other sites.
- FPP FY27 launches: At least five new products are expected to be launched out of the company's own portfolio next year, arriving at various times; management declined to quantify market sizes.
Aditi Panandikar: "I would say when it comes to Warren Remedies, let them breathe and grow sales."
Margins & Costs: Structural Lift, One-Time Drags
- Gross margin improved ~300 bps sequentially: Both subsidiaries started doing better after previously being a drain, and COGS at the standalone level improved, reflecting a better portfolio mix and business quality.
- Other expenses at INR169 cr include one-timers: The figure contains nonrecurring costs: remediation costs pending, costs associated with certain penalties, and penalties against orders for products not supplied due to the site under remediation. Management is confident of keeping other expenses at INR150 cr on a consolidated basis going forward.
- Debt repayment on track: INR28 crores of repayment is scheduled in Q4; management is confident of generating revenue and cash margins to fund both repayment and interest. Total consolidated debt is expected to decline from INR920 crores to around INR775-800 crores by end of March 2027, per an analyst's math confirmed by management.
- No margin loss from supply issues: Management clarified there is no margin loss from the supply constraints, only one-time costs for tech transfer activities.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Europe Q4 recovery | Q4 to be much better; Phase II MMP issues resolved, approval for higher batches, new sites coming in | Q4 FY26 |
| Europe revenue aspiration | Reach INR400-500 cr | FY28 or FY29 |
| Europe growth rate | 20% plus revenue growth with improving margins | Over next few years |
| API ramp-up from Auric | Start getting high revenues from Auric site | In another 8-10 months |
| US business | Return to INR300 crores at better margins than earlier | Definite visibility (undated) |
| OTC business growth | Number to go up safely by at least 30% | Next year (FY27) |
| FPP new launches | At least five new products from own portfolio | FY27 (at various times) |
| Other expenses | Confident to keep at INR150 cr on consolidated basis | Going forward |
| Debt reduction | Total consolidated debt down from INR920 cr to ~INR775-800 cr | By end of March 2027 |
| India business growth | Double-digit growth; not confident about 15% | Going forward |
| India business vs IPM | Able to do IPM levels or better | Going forward |
Key Metrics
| Metric | Q3 FY26 |
|---|---|
| Consolidated net revenues | ₹434.3 cr, +7.9% YoY and -7.9% QoQ |
| Standalone net revenues | ₹389.6 cr, +6.8% YoY and -9% QoQ |
| Consolidated EBITDA to sales | 7.3% at ₹31.5 cr, vs 3% at ₹12 cr same quarter last year; vs 9.2% at ₹43.1 cr in Q2 FY26 |
| Standalone EBITDA to net sales | 6.6% at ₹25.9 cr, vs 5.5% at ₹20.1 cr same quarter last year; vs 12.4% at ₹53.4 cr in Q2 FY26 |
| Consolidated gross profit margin | 73%, improved from 68% over last 3 quarters; sequential improvement of around 300 bps |
| Domestic formulation revenues | ₹214.2 cr, vs ₹224.1 cr same quarter last year |
| International formulation revenues | ₹135.6 cr, +26.2% YoY |
| US business revenues | ₹34.1 cr, +21.6% YoY |
| Europe revenues | ₹48.5 cr, +36.9% YoY |
| Emerging markets revenues | ₹49.5 cr, +26.8% YoY |
| API business revenues | ₹34.4 cr, +24% YoY |
| OTC business revenues | ₹34 cr this quarter; ₹94 cr YTD |
| Warren Remedies growth | +43% this quarter; +38% YTD |
| New introductions to India sales | 6.5% of India revenues |
| IQVIA prescription audit rank | 21st on MAT basis, with 10.86 cr prescriptions |
| Total consolidated debt | ~₹920 cr, comprising ₹700 cr in main business and ₹220 cr in WRPL; long-term debt at ₹590 cr |
| One-time costs (remediation, penalties, tech transfer) | ~₹35-40 cr in FY26 (per an analyst's math), including ~₹8-9 cr in penalties and remediation this quarter and ~₹20 cr annual tech transfer costs |
| Provision for new Labour Code | ₹7 cr |